ESR1 and breast carcinoma: All of the tumors that were tested for receptor status in our survey were ER+, suggesting preventative selective estrogen receptor modulators may be effective breast cancer prevention among PJS patients, as has been demonstrated among other patients at high risk for ER + tumors [69–71].